- Zacks•18 days ago
The availability of the AR-V7 serves as a further development to Genomic Health's (GHDX) recently launched Oncotype SEQ Liquid Select, a next-generation, liquid biopsy test.
- The Wall Street Journal•21 days ago
Genomic Health has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional ...
|Bid||28.49 x 100|
|Ask||28.64 x 200|
|52wk Range||20.05 - 35.79|
|Day's Range||28.46 - 28.75|
|Avg Vol (3m)||187,542|
As of 10:24 AM EDT. NasdaqGS Real Time Price. Market open.